WELLINGTON, Fla., Feb. 27, 2006 (PRIMEZONE) -- Ken Weiner, publisher of Shazamstocks.com, today announced profile coverage of BrainStorm Cell Therapeutics (OTCBB:BCLI). The profile is a comprehensive look at the company's growth initiative. You can view the complete profile at http://www.shazamstocks.com/profiles/bcli/index.php.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing the neural-like stem cell therapeutic product NurOwn(tm), based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(tm) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.
About Shazamstocks.com
Shazamstocks.com publishes profiles on up and coming publicly traded companies. Shazamstocks.com is one of the nation's top Internet destinations for small cap stock information. To feature your company, please call Ken Weiner, our Publisher at (561) 793-2665 or email editor@shazamstocks.com.
Disclosure: Shazamstocks.com has been compensated by a third party Tayside Corp Up to 150,000 restricted shares of BCLI. Details can be found at http://www.shazamstocks.com
Forward-Looking Statements
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.